Pre-clinical study.
Agree it is undervalued, however AGN is several years ahead on the clinical timeline - having completed a phase 1 and started dosing in a placebo-controlled double-blind phase 2. Plus ODD designation for HIE. I'd argue that AGN is also undervalued.
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $69.60M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.3¢ | 32.5¢ | $195.9K | 589.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14970 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 20100 | 1 |
View Market Depth
| Last trade - 15.29pm 25/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |